Details for Patent: 9,149,532
✉ Email this page to a colleague
Which drugs does patent 9,149,532 protect, and when does it expire?
Patent 9,149,532 protects SAVAYSA and is included in one NDA.
This patent has forty-one patent family members in twenty-nine countries.
Summary for Patent: 9,149,532
| Title: | Pharmaceutical composition |
| Abstract: | To provide pharmaceutical preparation exhibiting satisfactory dissolution property in a wide pH range. The pharmaceutical composition is characterized by containing (A) N.sup.1-(5-chloropyridin-2-yl)-N.sup.2-((1S,2R,4S)-4-[(dimethylamino)carb- onyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl- ]amino}cyclohexyl)ethanediamide, represented by the following formula (1), a pharmacologically acceptable salt thereof, or a hydrate of any of these, and (B) one or more species selected from the group consisting of a sugar alcohol and a water-swelling additive. ##STR00001## |
| Inventor(s): | Kojima; Masazumi (Shinagawa-ku, JP), Kuno; Yoshio (Shinagawa-ku, JP), Nakagami; Hiroaki (Shinagawa-ku, JP), Sagasaki; Shinji (Shimada, JP), Ishidoh; Koichi (Hiratsuka, JP), Sekiguchi; Gaku (Hiratsuka, JP) |
| Assignee: | Daiichi Sanykyo Company, Limited (Tokyo, JP) |
| Application Number: | 13/968,776 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Dosage form; Formulation; |
Drugs Protected by US Patent 9,149,532
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc | SAVAYSA | edoxaban tosylate | TABLET;ORAL | 206316-001 | Jan 8, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Daiichi Sankyo Inc | SAVAYSA | edoxaban tosylate | TABLET;ORAL | 206316-002 | Jan 8, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Daiichi Sankyo Inc | SAVAYSA | edoxaban tosylate | TABLET;ORAL | 206316-003 | Jan 8, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,149,532
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2007-087327 | Mar 29, 2007 |
International Family Members for US Patent 9,149,532
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2140867 | ⤷ Sign Up | PA2018005 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2140867 | ⤷ Sign Up | C20180004 00246 | Estonia | ⤷ Sign Up |
| European Patent Office | 2140867 | ⤷ Sign Up | PA2018005,C2140867 | Lithuania | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
